These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32186250)

  • 1. Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report.
    Barbosa MG; Delfino RS; Sarin LM; Jackowski AP
    Palliat Med; 2020 Jun; 34(6):822-825. PubMed ID: 32186250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
    Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L
    Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
    BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urothelial toxicity of esketamine in the treatment of depression.
    Findeis H; Sauer C; Cleare A; Bauer M; Ritter P
    Psychopharmacology (Berl); 2020 Nov; 237(11):3295-3302. PubMed ID: 32712681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression.
    Fava VAR; Sarin LM; Lucchese AC; Del Sant L; Magalhães E; Delfino RS; Tuena MA; Nakahira C; Jackowski AP; Abdo G; Surjan J; Steiglich M; Barbosa MG; Porto JAD; Lacerda ALT; Cogo-Moreira H
    Rev Psiquiatr Salud Ment (Engl Ed); 2021; 14(4):212-217. PubMed ID: 34861929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine in depression and electroconvulsive therapy.
    Rozet I
    Curr Opin Anaesthesiol; 2021 Oct; 34(5):556-562. PubMed ID: 34435599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial.
    Zhou Y; Ma B; Sun W; Wang J; Fu Y; Wang A; Wang G; Han R
    BMJ Open; 2022 Apr; 12(4):e056713. PubMed ID: 35473735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.